第一条 为规范公司行为，保证股东会依法行使职权，根据《中华人民共和 国公司法》（以下简称《公司法》）《中华人民共和国证券法》（以下简称《证 券法》）《上市公司股东会规则》《上市公司治理准则》《上海证券交易所股票 上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》和《公 司章程》等法律、行政法规、部门规章、规范性文件制定本规则。 第二条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 上海开开实业股份有限公司 股东会议事规则 第一章 总则 第三条 股东会应当在《公司法》和公司章程规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的 6 个月内举行。临时股东会不定期召开，出现《公 司法》第一百一十三条规定的应当召开临时股东会的情形时，临时股东会应当在 2 个月内召开。 公司在上述期限内不能召开股东会的，应当报告公司所在地中国证监会派出 机构和公司股票挂牌交易的证券交 ...

上海开开实业股份有限公司 关联交易实施细则 第一章 总 则 第一条 为规范上海开开实业股份有限公司（以下简称"公司"）关联交易 行为，提高公司规范运作水平，保护公司和全体股东的合法权益，根据《上海证 券交易所股票上市规则》（以下简称《股票上市规则》）、《公开发行证券的公司信 息披露内容与格式准则第2号<年度报告的内容与格式>》《上海证券交易所上市公 司自律监管指引第5号——交易与关联交易》等规定，制定本实施细则。 第二条 公司关联交易应当定价公允、决策程序合规、信息披露规范。公司 应当积极通过资产重组、整体上市等方式减少关联交易。 第三条 公司董事会规定其下设的审计委员会履行公司关联交易控制并督导 公司内部审计部门对关联交易的实施情况进行检查。 第四条 公司临时报告和定期报告中非财务报告部分的关联人及关联交易的 披露应当遵守《股票上市规则》和《公开发行证券的公司信息披露内容与格式准 则第 2 号<年度报告的内容与格式>》的规定。 定期报告中财务报告部分的关联人及关联交易的披露应当遵守《企业会计准 则第 36 号——关联方披露》的规定。 第五条 公司及其关联人违反《上市公司自律监管指引第 5 号——交易与关 联 ...

上海开开实业股份有限公司 董事会审计委员会实施细则 第一章 总则 第一条 为强化董事会决策功能，做到事前审计、专业审计，确保董事会对 经理层的有效监督，完善公司治理结构，根据《中华人民共和国公司法》《上市 公司治理准则》《公司章程》及其他有关规定，公司特设立董事会审计委员会， 并制定本实施细则。 第五条 审计委员会设主任委员(召集人)一名，由独立董事中会计专业人士 委员担任，负责主持委员会工作；主任委员在委员内选举，并报请董事会批准产 生。 第六条 审计委员会任期与董事会一致，委员任期届满，连选可以连任。期 间如有委员不再担任公司董事职务，自动失去委员资格，并由委员会根据上述第 三至第五条规定补足委员人数。 第七条 审计委员会下设公司内部审计部门，负责日常工作联络和会议组织 等工作。 - 1 - 第三章 职责权限 第八条 审计委员会的主要职责是： （一）监督及评估外部审计工作，提议聘请或更换外部审计机构； 第二条 董事会审计委员会是董事会按照股东会决议设立的专门工作机构， 主要负责审核公司财务信息及其披露、监督及评估内外部审计工作和内部控制。 第二章 人员组成 第三条 审计委员会委员由三名不在公司担任高级管理 ...

上海开开实业股份有限公司 募集资金使用管理办法 第一章 总 则 第一条 为规范上海开开实业股份有限公司（以下简称"公司"）对募集资 金的管理和使用，提高募集资金的使用效益，保护投资者的合法权益，依据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司募集资金监管规则》 《上海证券交易所上市公司自律监管指引第1号——规范运作》《上海证券交易 所股票上市规则》（以下简称"上市规则"）等法律、法规、部门规章、业务规 则及《公司章程》的规定，结合公司实际情况，制定本办法。 第二条 本办法所称募集资金系指公司通过公开发行证券(包括首次公开发 行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换公司债券、 公司债券、权证等)以及向特定对象发行证券向投资者募集的资金，但不包括公 司实施股权激励计划募集的资金。 第三条 本办法是公司对募集资金存储、使用和管理的内部控制制度,对公 司募集资金的存储、使用、变更、监督和责任追究等内容进行了明确规定。 公司及时将本管理办法报上海证券交易所备案并披露。 第四条 公司的董事和高级管理人员应当勤勉尽责，督促公司规范使用募集 资金，自觉维护公司募集资金安全，不得参与、协助或 ...

Core Viewpoint - The company reported a revenue increase in the third quarter but experienced a significant decline in net profit compared to the previous year [1] Financial Performance - Third quarter revenue reached 282 million yuan, representing a year-on-year growth of 10.38% [1] - Net profit for the third quarter was 1.067 million yuan, showing a year-on-year decline of 70.33% [1] - Revenue for the first three quarters totaled 825 million yuan, with a year-on-year increase of 10.76% [1] - Net profit for the first three quarters was 12.8678 million yuan, reflecting a year-on-year decrease of 62.81% [1]

Market Overview - The primary economic sector increased by 0.25% compared to the previous trading day, with *ST Yazhen leading the gains [1] - The Shanghai Composite Index closed at 3988.22, down 0.22%, while the Shenzhen Component Index closed at 13430.1, down 0.44% [1] Stock Performance - The top-performing stocks in the primary economic sector included: - *ST Yazhen: Closed at 48.25, up 3.70% with a trading volume of 45,900 shares and a turnover of 218 million yuan [1] - Shanghai Phoenix: Closed at 13.53, up 3.28% with a trading volume of 202,500 shares and a turnover of 275 million yuan [1] - Remote Technology: Closed at 6.94, up 3.12% with a trading volume of 805,000 shares and a turnover of 557 million yuan [1] Capital Flow - The primary economic sector experienced a net outflow of 87.83 million yuan from institutional investors, while retail investors saw a net inflow of 67.43 million yuan [2] - The capital flow for individual stocks showed: - Remote Technology had a net inflow of 38.64 million yuan from institutional investors, but a net outflow of 56.11 million yuan from retail investors [3] - Shanghai Phoenix saw a net inflow of 8.56 million yuan from institutional investors, with a net outflow of 21.73 million yuan from speculative funds [3]

Market Overview - The pharmaceutical commercial sector increased by 0.44% on October 23, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Jianfa Zhixin (301584) saw a significant rise of 20.00%, closing at 37.20 with a trading volume of 301,100 shares and a transaction value of 1.046 billion [1] - Other notable performers included: - Kaikai Industrial (600272) up 2.20% to 13.49 [1] - First Pharmaceutical (600833) up 1.97% to 14.01 [1] - Dazhenlin (603233) up 1.48% to 19.20 [1] - Yifeng Pharmacy (603939) up 1.31% to 25.44 [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 97.0483 million from institutional investors and 117 million from speculative funds, while retail investors saw a net inflow of 214 million [2] - The capital flow for key stocks showed: - Jianfa Zhixin had a net inflow of 1.22 billion from institutional investors, but a net outflow of 58.2871 million from speculative funds [3] - Kaikai Industrial had a net inflow of 15.4487 million from institutional investors, with a net outflow of 3.9622 million from speculative funds [3]

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

Core Viewpoint - The stock of Kaikai Industrial has shown a mixed performance in recent trading, with a year-to-date decline of 13.68% but a recent uptick of 3.72% over the last five trading days [1] Company Overview - Kaikai Industrial Co., Ltd. is located in Changping Road, Jing'an District, Shanghai, and was established on August 4, 1997. The company was listed on February 28, 2001. Its main business involves traditional Chinese medicine distribution, Chinese medicine services (consultation), and clothing wholesale and retail [1] - The revenue composition of the company is as follows: wholesale 74.48%, retail 18.18%, health services 4.42%, leasing 1.77%, and others 1.14% [1] Financial Performance - For the first half of 2025, Kaikai Industrial achieved a revenue of 543 million yuan, representing a year-on-year growth of 10.95%. However, the net profit attributable to shareholders decreased by 61.94% to 11.801 million yuan [2] - Since its A-share listing, the company has distributed a total of 191 million yuan in dividends, with 34.749 million yuan distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders for Kaikai Industrial was 36,200, a decrease of 9.45% from the previous period. The average circulating shares per person remained at 0 [2] - Among the top ten circulating shareholders, China Merchants Securities (Hong Kong) Co., Ltd. is the fifth largest with 1.1311 million shares, while the China Securities Shanghai State-owned Enterprise ETF (510810) is the sixth largest with 951,700 shares, an increase of 73,000 shares from the previous period. BOCI Securities Limited is the ninth largest shareholder with 862,700 shares, marking a new entry [3]